PharmGen Science, Inc.

KSE 004720.KS

PharmGen Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 3.35%

PharmGen Science, Inc. Return on Capital Employed (ROCE) is 3.35% for the year ending December 31, 2023, a 12.51% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

PharmGen Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 2.97%, a 189.86% change year over year.
PharmGen Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -3.31%, a -69.97% change year over year.
PharmGen Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -1.95%, a -213.34% change year over year.
PharmGen Science, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 1.72%, a -77.34% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KSE: 004720.KS

PharmGen Science, Inc.

CEO	Lee Seung-Yeol
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	50, Jeyakgongdan 2-gil
Employees	248
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.

Key trends

Past 5 years